SAN DIEGO, April 11, 2024 /PRNewswire/ -- Neurelis, Inc. will present a poster on VALTOCO® (diazepam nasal spray) for the treatment of episodes of frequent seizure activity (i.e., seizure clusters) in patients with epilepsy ages 6 to 65 years, describing the time to treatment across different subpopulations. A second presentation will provide insight into characterization of a repeat-dosing model for preclinical diazepam studies. These findings will be showcased through posters at the 76th Annual Meeting of the American Academy of Neurology (AAN) in Denver from April 13 to 18, offering both in-person attendance and live online participation in a hybrid format.
Neurelis Announces Presentations At The American Epilepsy Society Annual Meeting
SAN DIEGO, Nov. 27, 2023 /PRNewswire/ -- Neurelis, Inc., a neuroscience company focused on the development and commercialization of therapeutics for the treatment of epilepsy and orphan neurologic disorders characterized by high unmet medical need, announced that it has secured the issuance of United States Patent No. 11,793,786 (the '786 Patent). The '786 Patent covers VALTOCO® and other pharmaceutical solutions for nasal administration consisting of diazepam or a pharmaceutically acceptable salt thereof in combination with specific ranges of one or more natural or synthetic tocopherols or tocotrienols, benzyl alcohol, and n-dodecyl beta-D-maltoside.
Neurelis to Participate in the 6th Annual Evercore ISI HealthCONx Conference
SAN DIEGO, Oct. 30, 2023 /PRNewswire/ -- Neurelis Inc., is proud to take part in the 11th Annual Sofie's Journey Epilepsy Awareness Day and Education Expo at Disneyland Resort (EADDL), the largest, worldwide epilepsy community gathering of the year. The event kicks off with a free Expo on Oct. 30 and Oct. 31, 9:00 a.m. to 5:00 p.m. at the Disneyland Hotel Convention Center. Epilepsy Awareness Day will take place on Nov. 1, at Disneyland Resort.
SAN DIEGO, Oct. 4, 2023 /PRNewswire/ -- Neurelis, Inc., today announced additional findings from the post hoc analysis of the long-term phase 3 safety study of VALTOCO® (diazepam nasal spray) in a pediatric population, aged 6-17 years, as well as an analysis of real-world data on impact of administration of rescue medication on seizure timing. A total of four posters will be presented at the 52nd Child Neurology Society Annual Meeting in Vancouver, BC, Canada, October 4 – 7, 2023. The Child Neurology Society's mission is to raise awareness about the importance of child neurologists and the health needs of children with chronic neurological conditions.
SAN DIEGO, Aug. 31, 2023 /PRNewswire/ -- Neurelis, Inc. will present additional clinical findings from the completed long-term, open-label, repeat-dose safety study of VALTOCO for the treatment of episodes of frequent seizure activity (i.e., seizure clusters) in people with epilepsy for ages 6 to 65 at the 35th International Epilepsy Congress (IEC) in Dublin, Ireland, September 2 to 6. The congress is organized by the International League Against Epilepsy (ILAE) and International Bureau for Epilepsy (IBE).
NEURELIS ANNOUNCES FOUR POSTER PRESENTATIONS AT THE 75TH ANNUAL MEETING OF THE AMERICAN ACADEMY OF NEUROLOGY
SAN DIEGO, Calif., March 24, 2023 /PRNewswire/ -- Neurelis, Inc., announced the first two cohorts dosed in the investigational clinical trial of NRL-1049, a Rho kinase (ROCK) inhibitor, a potential treatment for people living with cerebral cavernous malformations (CCM), a disease characterized by abnormally enlarged capillary cavities in the brain and spinal cord. This is a first-in-human study designed to establish safety, tolerability, and pharmacokinetic parameters of NRL-1049.
SAN DIEGO, Jan. 9, 2023 /PRNewswire/ -- Neurelis, Inc., announced the successful filing of its investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for NRL-1049, a Rho kinase (ROCK) inhibitor with a potential treatment for people living with cerebral cavernous malformations (CCM), a disease characterized by abnormally enlarged capillary cavities in the brain and spinal cord.